Coffee and cancers of the upper digestive and respiratory tracts: Meta-analyses of observational studies

F. Turati, C. Galeone, C. La Vecchia, W. Garavello, A. Tavani

Research output: Contribution to journalArticle

Abstract

Background: Data of epidemiological studies on the relation between coffee drinking and upper aerodigestive tract cancer risk are scattered and inconclusive. We therefore conducted systematic meta-analyses of observational studies published before October 2009. Materials and methods: We combined relative risks (RR) with 95% confidence intervals (CI) for cancers of the oral cavity/pharynx (OP) and larynx, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), comparing the highest versus the lowest categories of coffee consumption, using random-effects models. Results: For OP cancer, the pooled RR was 0.64 (95% CI 0.51-0.80) for highest versus lowest coffee drinking, based on a total of 2633 cases from one cohort and eight case-control studies, with no significant heterogeneity across studies. The RRs were 0.61 (95% CI 0.41-0.89) for European, 0.58 (95% CI 0.36-0.94) for American and 0.74 (95% CI 0.48-1.15) for Asian studies, where coffee consumption is lower. The corresponding RRs were 1.56 (95% CI 0.60-4.02) for laryngeal cancer (732 cases from three case-control studies), 0.87 (95% CI 0.65-1.17) for ESCC (2115 cases from one cohort and six case-control studies) and 1.18 (95% CI 0.81-1.71) for EAC (415 cases from three case-control studies). Conclusion: Coffee drinking is inversely related to OP cancer risk, while there is no relation with laryngeal cancer, ESCC and EAC.

Original languageEnglish
Pages (from-to)536-544
Number of pages9
JournalAnnals of Oncology
Volume22
Issue number3
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Coffee
Respiratory System
Observational Studies
Meta-Analysis
Gastrointestinal Tract
Confidence Intervals
Case-Control Studies
Neoplasms
Pharyngeal Neoplasms
Drinking
Mouth
Adenocarcinoma
Laryngeal Neoplasms
Mouth Neoplasms
Larynx
Pharynx
Epidemiologic Studies

Keywords

  • Coffee
  • Esophageal cancer
  • Laryngeal cancer
  • Meta-analysis
  • Oral cancer
  • Pharyngeal cancer

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Coffee and cancers of the upper digestive and respiratory tracts : Meta-analyses of observational studies. / Turati, F.; Galeone, C.; La Vecchia, C.; Garavello, W.; Tavani, A.

In: Annals of Oncology, Vol. 22, No. 3, 03.2011, p. 536-544.

Research output: Contribution to journalArticle

Turati, F. ; Galeone, C. ; La Vecchia, C. ; Garavello, W. ; Tavani, A. / Coffee and cancers of the upper digestive and respiratory tracts : Meta-analyses of observational studies. In: Annals of Oncology. 2011 ; Vol. 22, No. 3. pp. 536-544.
@article{44c00ba9f1eb4b0bb4e41fea576259c4,
title = "Coffee and cancers of the upper digestive and respiratory tracts: Meta-analyses of observational studies",
abstract = "Background: Data of epidemiological studies on the relation between coffee drinking and upper aerodigestive tract cancer risk are scattered and inconclusive. We therefore conducted systematic meta-analyses of observational studies published before October 2009. Materials and methods: We combined relative risks (RR) with 95{\%} confidence intervals (CI) for cancers of the oral cavity/pharynx (OP) and larynx, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), comparing the highest versus the lowest categories of coffee consumption, using random-effects models. Results: For OP cancer, the pooled RR was 0.64 (95{\%} CI 0.51-0.80) for highest versus lowest coffee drinking, based on a total of 2633 cases from one cohort and eight case-control studies, with no significant heterogeneity across studies. The RRs were 0.61 (95{\%} CI 0.41-0.89) for European, 0.58 (95{\%} CI 0.36-0.94) for American and 0.74 (95{\%} CI 0.48-1.15) for Asian studies, where coffee consumption is lower. The corresponding RRs were 1.56 (95{\%} CI 0.60-4.02) for laryngeal cancer (732 cases from three case-control studies), 0.87 (95{\%} CI 0.65-1.17) for ESCC (2115 cases from one cohort and six case-control studies) and 1.18 (95{\%} CI 0.81-1.71) for EAC (415 cases from three case-control studies). Conclusion: Coffee drinking is inversely related to OP cancer risk, while there is no relation with laryngeal cancer, ESCC and EAC.",
keywords = "Coffee, Esophageal cancer, Laryngeal cancer, Meta-analysis, Oral cancer, Pharyngeal cancer",
author = "F. Turati and C. Galeone and {La Vecchia}, C. and W. Garavello and A. Tavani",
year = "2011",
month = "3",
doi = "10.1093/annonc/mdq603",
language = "English",
volume = "22",
pages = "536--544",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "3",

}

TY - JOUR

T1 - Coffee and cancers of the upper digestive and respiratory tracts

T2 - Meta-analyses of observational studies

AU - Turati, F.

AU - Galeone, C.

AU - La Vecchia, C.

AU - Garavello, W.

AU - Tavani, A.

PY - 2011/3

Y1 - 2011/3

N2 - Background: Data of epidemiological studies on the relation between coffee drinking and upper aerodigestive tract cancer risk are scattered and inconclusive. We therefore conducted systematic meta-analyses of observational studies published before October 2009. Materials and methods: We combined relative risks (RR) with 95% confidence intervals (CI) for cancers of the oral cavity/pharynx (OP) and larynx, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), comparing the highest versus the lowest categories of coffee consumption, using random-effects models. Results: For OP cancer, the pooled RR was 0.64 (95% CI 0.51-0.80) for highest versus lowest coffee drinking, based on a total of 2633 cases from one cohort and eight case-control studies, with no significant heterogeneity across studies. The RRs were 0.61 (95% CI 0.41-0.89) for European, 0.58 (95% CI 0.36-0.94) for American and 0.74 (95% CI 0.48-1.15) for Asian studies, where coffee consumption is lower. The corresponding RRs were 1.56 (95% CI 0.60-4.02) for laryngeal cancer (732 cases from three case-control studies), 0.87 (95% CI 0.65-1.17) for ESCC (2115 cases from one cohort and six case-control studies) and 1.18 (95% CI 0.81-1.71) for EAC (415 cases from three case-control studies). Conclusion: Coffee drinking is inversely related to OP cancer risk, while there is no relation with laryngeal cancer, ESCC and EAC.

AB - Background: Data of epidemiological studies on the relation between coffee drinking and upper aerodigestive tract cancer risk are scattered and inconclusive. We therefore conducted systematic meta-analyses of observational studies published before October 2009. Materials and methods: We combined relative risks (RR) with 95% confidence intervals (CI) for cancers of the oral cavity/pharynx (OP) and larynx, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), comparing the highest versus the lowest categories of coffee consumption, using random-effects models. Results: For OP cancer, the pooled RR was 0.64 (95% CI 0.51-0.80) for highest versus lowest coffee drinking, based on a total of 2633 cases from one cohort and eight case-control studies, with no significant heterogeneity across studies. The RRs were 0.61 (95% CI 0.41-0.89) for European, 0.58 (95% CI 0.36-0.94) for American and 0.74 (95% CI 0.48-1.15) for Asian studies, where coffee consumption is lower. The corresponding RRs were 1.56 (95% CI 0.60-4.02) for laryngeal cancer (732 cases from three case-control studies), 0.87 (95% CI 0.65-1.17) for ESCC (2115 cases from one cohort and six case-control studies) and 1.18 (95% CI 0.81-1.71) for EAC (415 cases from three case-control studies). Conclusion: Coffee drinking is inversely related to OP cancer risk, while there is no relation with laryngeal cancer, ESCC and EAC.

KW - Coffee

KW - Esophageal cancer

KW - Laryngeal cancer

KW - Meta-analysis

KW - Oral cancer

KW - Pharyngeal cancer

UR - http://www.scopus.com/inward/record.url?scp=79952033099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952033099&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq603

DO - 10.1093/annonc/mdq603

M3 - Article

C2 - 20943597

AN - SCOPUS:79952033099

VL - 22

SP - 536

EP - 544

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -